# A Multicentre, Retrospective-prospective Real-world Study: to Evaluate the Effectiveness and Safety of Vorasidenib in Patients With Isocitrate Dehydrogenase IDH1/2 Mutant Grade 2 Astrocytoma or Oligodendroglioma (VICTORIA Study)

> **NCT06969352** · — · NOT_YET_RECRUITING · sponsor: **Servier (Tianjin) Pharmaceutical Co. LTD.** · enrollment: 60 (estimated)

## Conditions studied

- Gliomas

## Interventions

- **DRUG:** Vorasidenib

## Key facts

- **NCT ID:** NCT06969352
- **Lead sponsor:** Servier (Tianjin) Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06
- **Primary completion:** 2026-10
- **Final completion:** 2027-02
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-05-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06969352

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06969352, "A Multicentre, Retrospective-prospective Real-world Study: to Evaluate the Effectiveness and Safety of Vorasidenib in Patients With Isocitrate Dehydrogenase IDH1/2 Mutant Grade 2 Astrocytoma or Oligodendroglioma (VICTORIA Study)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06969352. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*